Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Krishan R. Jethwa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7590-558X; OpenAlex author ID A5083871900, A5095415399. Sources: ClinicalTrials.gov.

Their work

Papers
11 (first author 5, last author 3)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
36
Papers, trials and grants by year

2018: 1 trial · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 5 papers

Papers 11

  1. Innovative Targets, New Technologies, Same Tenacity: Radiation Therapy's Evolving Role in Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2025.11.058↗
  2. Elective Target Volume Delineation for Locally Advanced Pancreatic Cancer. First author DOI 10.1016/j.prro.2025.08.007↗
  3. Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline. First author DOI 10.1016/j.prro.2026.07.002↗
  4. The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer. First author DOI 10.1016/s1470-2045(25)00666-7↗
  5. Peri-operative radiotherapy for pancreatic ductal adenocarcinoma: current evidence and future directions: a narrative review. First author DOI 10.21037/cco-25-98↗
  6. Contemporary Advances, Evidence, and Considerations in Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.semradonc.2025.07.007↗
  7. Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma: Systematic Revie… Co-author DOI 10.1097/coc.0000000000001076↗
  8. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer. Last author DOI 10.2147/ceg.s341189↗
  9. Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial. First author DOI 10.1001/jamaoncol.2022.6135↗
  10. Patterns of Recurrence After Primary Local Therapy for Pancreatic Ductal Adenocarcinoma - A Critical Review of Rationale and Target Delineation for (Neo)Adjuva… Co-author DOI 10.1016/j.prro.2022.06.004↗
  11. Time to Reconsider Staging Laparoscopy in Pancreatic Cancer? Last author DOI 10.1200/jco.20.00996↗

Trials 1

  1. A Study of Photon and Proton Chemoradiotherapy as Definitive or Neoadjuvant Therapy in Non-Metastatic Pancreatic Cancer Principal investigator NCT03902600↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alexandra K. Bennett · 2 shared papers, 2025–2026 · strength 0.96
  2. Alexander Dean Sherry · 2 shared papers, 2025–2026 · strength 0.76
  3. Ethan Bernard Ludmir · 2 shared papers, 2026 · strength 0.65
  4. Ayah Erjan · 1 shared paper, 2026 · strength 0.63
  5. Christopher Leigh Hallemeier · 3 shared papers, 2020–2024 · strength 0.57
  6. Shane S. Neibart · 2 shared papers, 2022–2024 · strength 0.56
  7. Michael David Chuong · 2 shared papers, 2026 · strength 0.54
  8. Mark Joseph Truty · 2 shared papers, 2022–2025 · strength 0.53
  9. Salma K. Jabbour · 2 shared papers, 2022–2024 · strength 0.38
  10. Shalini Moningi · 1 shared paper, 2024 · strength 0.36
  11. Ryan Michael Carr · 1 shared paper, 2025 · strength 0.33
  12. Eric David Miller · 1 shared paper, 2026 · strength 0.32
  13. Luca Boldrini · 1 shared paper, 2026 · strength 0.32
  14. Aaron J. Grossberg · 1 shared paper, 2023 · strength 0.31
  15. Susannah G. Ellsworth · 1 shared paper, 2023 · strength 0.31
  16. Rachna T. Shroff · 1 shared paper, 2026 · strength 0.22
  17. Michael Frederick Bassetti · 1 shared paper, 2026 · strength 0.22
  18. Nina Niu Sanford · 1 shared paper, 2026 · strength 0.22
  19. Marsha Reyngold · 1 shared paper, 2026 · strength 0.22
  20. Jessica M. Frakes · 1 shared paper, 2026 · strength 0.22
  21. Karyn A. Goodman · 1 shared paper, 2026 · strength 0.22
  22. Thomas Baptist Brunner · 1 shared paper, 2026 · strength 0.22
  23. Diego A.S. Toesca · 1 shared paper, 2026 · strength 0.22
  24. Daniel Tandel Chang · 1 shared paper, 2026 · strength 0.22
  25. Susan Tsai · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.